Avaz

Avaz is an augmentative-and-alternative-communication (AAC) software company whose core product is a symbol-based speech app for iPad, iPhone and Android tablets. The flagship Avaz AAC app is sold as a one-time download priced in the mid-range tier (≈ US $99–$159) with optional in-app vocabulary packs; a separate web-based dashboard for educators and therapists is subscription-based. Sales are handled exclusively through the Apple App Store, Google Play Store and the company’s own site; no physical retail distribution exists. Complementary offerings include Avaz Live (remote therapy screen-sharing) and a freemium story-building literacy app, keeping the catalogue tightly focused on digital communication aids. The brand’s differentiation lies in its linguistically engineered, graded core-word vocabulary that can be progressively revealed as a child’s language grows, and in built-in analytics that log every tap to generate automatic progress reports for therapists. Avaz was the first AAC app to add native Zoom-style tele-therapy, letting specialists coach users without leaving the app. Its picture library supports 40,000 SymbolStix, regional language packs (Hindi, Spanish, French, Danish) and user-recorded audio, making the product a reference choice in multilingual special-education classrooms. Primary buyers are parents of children with autism, cerebral palsy, aphasia or childhood apraxia who need an immediate, evidence-based voice-output tool; special-education teachers and speech-language pathologists purchase institutional licenses to standardize therapy across districts. The brand appeals to value-driven caregivers who want research-backed language growth, measurable IEP data and the flexibility to move from picture exchange to full grammar without switching software. Avaz competes in the niche but crowded AAC app segment populated by both low-cost symbol boards and high-end dedicated speech devices; it positions itself between the two by offering pro-level linguistic depth at a consumer-tablet price while remaining FDA/CE registered as a Class-I medical software. Continuous updates, region-specific localization and therapist-designed lesson plans give it an edge over freemium drawing-board apps, whereas its portability and subscription-free core license undercut locked-ecosystem hardware competitors.